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Summary
Background Although cannabis use after a ﬁ rst episode of psychosis has been associated with relapse, little is known 
about the determinants of this most preventable risk factor for relapse of psychosis. Here we aimed to study whether 
the eﬀ ects on outcome vary depending on the type of cannabis consumed and usage pattern.
Methods In this observational study, we prospectively recruited and followed up patients aged 18–65 years who 
presented with their ﬁ rst episode of psychosis to psychiatric services in south London, London, UK. Relapse of 
psychosis within 2 years after onset of psychosis was deﬁ ned as risk of subsequent admission to hospital. We classiﬁ ed 
patients into diﬀ erent patterns of cannabis use based on continuity of use after onset of psychosis, potency of cannabis 
consumed, and frequency of use after the onset of their illness. We used multiple regression analyses (logistic or 
binominal) to compare the diﬀ erent cannabis use groups and propensity score analysis to validate the results.
Findings Between April 12, 2002, and July 26, 2013, 256 patients presented with a ﬁ rst episode of psychosis. We did 
follow-up assessments for these patients until September, 2015. Simple analyses showed that former regular users 
of cannabis who stopped after the onset of psychosis had the most favourable illness course with regards to relapse. 
In multiple analysis, continued high-frequency users (ie, daily use in all 24 months) of high-potency (skunk-like) 
cannabis had the worst outcome, indexed as an increased risk for a subsequent relapse (odds ratio [OR] 3·28; 95% 
CI 1·22–9·18), more relapses (incidence rate ratio 1·77; 95% CI 0·96–3·25), fewer months until a relapse occurred 
(b –0·22; 95% CI –0·40 to –0·04), and more intense psychiatric care (OR 3·16; 95% CI 1·26–8·09) after the onset of 
psychosis.
Interpretation Adverse eﬀ ects associated with continued use of cannabis after the onset of a ﬁ rst episode of psychosis 
depend on the speciﬁ c patterns of use. Possible interventions could focus on persuading cannabis-using patients with 
psychosis to reduce use or shift to less potent forms of cannabis.
Funding National Institute for Health Research (NIHR).
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Introduction
In the past 30 years, ﬁ ndings of studies have shown that 
cannabis use is a contributory cause of psychotic 
disorders, especially if used often and initiated at an early 
age.1,2 Cannabis remains the most commonly used illicit 
drug in patients with established psychosis3 and use is 
especially high in young people presenting with their 
ﬁ rst episode of psychosis.4 Only a few patients with 
established psychosis start using cannabis after onset of 
psychosis,5 but a major concern is the substantial 
proportion who continue using the drug.6 Findings of a 
recent meta-analysis suggest that continued cannabis 
use after the onset of psychosis predicts poor disease 
outcome as shown by a high number of relapses, 
admittance to hospital, and more severe positive 
symptomatology.7 These ﬁ ndings are consistent with 
evidence that experimental administration of the key 
psychoactive ingredient in cannabis is associated with 
transient psychotic symptoms and cognitive impairments 
in healthy individuals and exacerbation of symptoms in 
patients with a pre-existing psychotic disorder.8,9
However, whether the association between cannabis 
use and worse outcome in pre-existing psychosis is 
causal has remained inconclusive7 because prospective 
evidence so far has not always established that cannabis 
use actually preceded and was in reasonable temporal 
proximity to the outcome of interest (ie, relapse of 
psychosis). More importantly, how parameters of 
cannabis use, such as type and potency of cannabis used 
and frequency of use, aﬀ ect outcome has remained 
unclear. This gap in the scientiﬁ c literature is especially 
important in view of ﬁ ndings that dose, type, and 
pattern10 of cannabis use are important determinants of 
its eﬀ ect on onset of psychosis. In particular, for such 
evidence to be translated into real world meaningful 
solutions in the clinical setting, it is important to 
develop a more nuanced understanding of the 
association between one of the most potentially 
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preventable risk factors of psychosis—ie, cannabis use 
and its determinants and the risk of relapse in psychosis.
Understanding the role of cannabis in relapse of 
psychosis is important not just because prevention of 
relapse is crucial for improved long-term outcome in 
psychosis,11 but also because of the substantial ﬁ nancial 
implications associated with need for hospital care in 
those who relapse;12 up to 50% of ﬁ rst-episode psychosis 
patients experience a relapse that results in hospital 
admission within the ﬁ rst 2 years of illness, with the 
risk increasing to more than 80% by the eighth year.13
Here we investigate the eﬀ ects of continued cannabis 
use on risk of relapse as indexed by hospital admission 
over the ﬁ rst 2 years after the onset of psychosis.
Methods
Participants
We recruited patients with ﬁ rst-episode non-organic 
(non-aﬀ ective [ICD10 codes F20–F29]) or aﬀ ective 
[F30–F33]) psychosis,14 aged 18–65 years who had been 
admitted to psychiatric services in South London, 
London, UK. Participants were assessed twice, ﬁ rst 
close to the onset of their illness using face-to-face 
interviews and subsequently for follow up, using either 
a face-to-face or a telephone interview (if the individual 
was unable to attend interviews in person). Data from 
clinical records regarding hospital admissions were 
collected for participants who refused to take part in the 
follow-up interview (n=133) during the 2 years after 
psychosis onset. The study was approved by South 
London and Maudsley NHS Foundation Trust and 
Institute of Psychiatry Local Research Ethics Committee. 
All participants included in the study gave written 
informed consent.
Outcomes
We assessed cannabis use with a modiﬁ ed version of the 
Cannabis Experience Questionnaire (CEQmv),10 and 
collected data for premorbid cannabis use, and use in 
the ﬁ rst 2 years after onset of psychosis. Cannabis users 
were classiﬁ ed into diﬀ erent cannabis use proﬁ les based 
on their pattern of use depending on continuity and 
frequency of cannabis use after onset of psychosis. Type 
of cannabis (hash-like vs skunk-like) used was assessed 
by asking participants to describe their preferred type of 
cannabis. Based on this information, grouping was done 
in the same way as reported previously,10 Information 
about service use, number, duration and legal status 
(voluntary or involuntary) of inpatient admissions, 
referral to crisis intervention team or standard treatment 
by a community mental health team was obtained from 
electronic patient records using established methods 
(appendix). Relapse was deﬁ ned as admission to a 
psychiatric inpatient unit because of exacerbation of 
psychotic symptoms within 2 years of ﬁ rst presentation 
to psychiatric services and diagnosis of psychosis. If the 
patient was admitted to hospital upon ﬁ rst presentation 
to psychiatric services with a diagnosis of psychosis, this 
Research in context
Evidence before this study
In January, 2016, we published a meta-analysis in The Lancet 
Psychiatry, wherein we studied the eﬀ ect of continued cannabis 
use on the risk of relapse in patients with psychosis. In this 
meta-analysis, we searched MEDLINE for articles published in 
any language until April, 2015, using a combination of search 
terms for describing the exposure (cannabis use), the outcome 
of interest (relapse of psychosis), and the study population 
(patients with psychosis). Data were pooled together from 
24 studies (16 565 participants) to compare relapse outcomes 
in the following groups: continued cannabis users, discontinued 
cannabis users, and non-users. Continued cannabis users had 
more relapses and longer stays in hospital compared with 
non-users. These adverse eﬀ ects were not recorded in patients 
who discontinued cannabis use after the onset of psychosis. An 
update of the search (April 11, 2016, 129 included studies) 
identiﬁ ed two additional studies (appendix p 4), which 
conﬁ rmed an increased risk for relapse related to cannabis use 
in ﬁ rst episode psychosis and hospital admissions in patients 
with established schizophrenia.
Added value of this study
Our ﬁ ndings add to the evidence on cannabis use and relapse in 
psychosis. For the ﬁ rst time, we used a detailed assessment of 
distinct cannabis use proﬁ les in a large sample of ﬁ rst episode 
psychosis patients and showed that the eﬀ ect on outcome 
varies depending on the type of cannabis consumed as well as 
usage pattern, after controlling for a range of important 
confounders previously not generally considered (eg, 
medication adherence or other illicit drug use). The results were 
validated for covariate adjustment (by using propensity score 
matching) and consistency (by using diﬀ erent measures of 
relapse, including risk and number of relapses, length of relapse, 
time until relapse, severity of relapse), and point towards 
potential targets for intervention.
Implications of all the available evidence
Continued cannabis use (at least monthly use) after the onset 
of psychosis, especially use of high-potency cannabis, is 
associated with a signiﬁ cantly worse outcome in individuals 
with ﬁ rst episode psychosis. In our study, outcomes were 
better in those who used cannabis in smaller doses (reduced 
frequency, lower potency, and shorter duration of 
continuation) after onset, which suggests that interventions 
should aim to reduce frequency of use or shift to less potent 
forms of cannabis when complete cessation of cannabis use 
might not be a realistic goal. 
See Online for appendix
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was not considered as a relapse event. Alcohol use, other 
illicit drug use, and cigarette use, care intensity at onset 
(as a proxy measure of illness severity based on a rating 
of intensity of service use for each subject at onset; 
appendix p 7), and medication adherence were assessed 
and included in the analysis as potential confounders 
based on previous scientiﬁ c literature. The appendix 
describes estimated measure ments of cannabis use, 
relapse, and confounders.
Statistical analysis
Data analysis was done with R. We modelled follow-up 
data for 2 years after the onset of psychosis for every 
participant. The cannabis proﬁ le variable was coded as an 
ordered categorical variable, with the former (regular) user 
group acting as the reference group (appendix). First, 
exploratory simple analyses, including χ² test for categorical 
variables and Kruskal-Wallis test and Mann-Whitney 
U (two-sided) test for continuous outcomes were used to 
compare the diﬀ erent cannabis use groups. Following 
common practice,2 we generated Kaplan-Meier curves and 
compared the diﬀ erent cannabis use groups using log-
rank tests. Pairwise comparisons were adjusted with 
Bonferroni correction to account for multiple testing. 
Multiple logistic regression analyses were employed to 
compute the odds ratio (OR) and 95% CIs, using binary 
logistic regression for binary outcomes (risk of relapse) 
and ordinal logistic regression analysis for ordered 
categorical outcome (care intensity at follow up). We used 
multiple negative binominal regression models for 
continuous outcomes (number of relapses, length of 
relapse, time to relapse; appendix). Sensitivity analysis was 
done by calculating propensity scores to validate the results 
and to address the limitations by confounding adjustment 
in regression analysis (appendix).15 We included anti-
psychotic medication adherence in a separate regression 
model because these data were available for only a subset 
of cases, considering that antipsychotic medications were 
not prescribed for all participans after the onset of illness.
Role of the funding source
The funder had no role in the design and conduct of the 
study; collection, management, analysis, and inter-
pretation of the data; preparation, review, or approval of 
the manuscript; and decision to submit the manuscript 
for publication. The corresponding author had full access 
to all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication. All authors have 
approved the ﬁ nal version of the paper.
Results
Between April 12, 2002, and July 26, 2013, we recruited 
256 ﬁ rst episode psychosis patients and did follow-up 
assessments until September, 2015. The two groups 
(completers and refusers) did not diﬀ er signiﬁ cantly in 
their risk of relapse (36% vs 38% relapsed, χ²= 0·15; 
p=0·70) and baseline characteristics (appendix  p 6). 
Most patients (200 [78%]) were admitted to hospital 
around the onset of illness; more than half of those (119 
[60%]) experienced involuntary admission. Within the 
ﬁ rst 2 years after onset of psychosis, 93 (36%) patients 
experienced a relapse leading to hospital admission. The 
highest number of relapses recorded was three, and the 
longest hospital stay recorded was 14·8 months within 
All participants Former (regular) 
cannabis user
Never (regular) 
cannabis user
Intermittent 
cannabis user
Continued 
cannabis user
p value*
Number of participants 256 (100%) 54 (21%) 103 (40%) 35 (14%) 64 (25%) ..
Age of onset 28·06 (8·03) 28·05 (7·65) 29·74 (8·96) 27·95 (8·21) 25·43 (5·83) 0·02
Men 156 (61%) 37 (69%) 44 (43%) 24 (69%) 51 (80%) <0·0001
Non-white ethnic origin 170 (66%) 23 (43%) 78 (76%) 22 (63%) 47 (73%) 0·0002
Care intensity at onset 0·71
Referral to community team only 39 (15%) 12 (22%) 15 (15%) 4 (11%) 8 (13%) ..
Required contact with crisis team 17 (7%) 5 (9%) 6 (6%) 2 (6%) 4 (6%) ..
Required hospital admission (non-compulsory) 81 (32%) 13 (24%) 38 (37%) 12 (34%) 18 (28%) ..
Required hospital admission (compulsory) 119 (47) 24 (44%) 44 (43%) 17 (49%) 34 (53%) ..
Months stayed in hospital at onset 1·72 (3·37) 2·10 (6·28) 1·57 (2·09) 1·31 (1·20) 1·88 (2·16) 0·57
Employment status at onset (n in employment)† 83 (33%) 21 (40%) 38 (37%) 9 (26%) 15 (24%) 0·15
Family history of mental illness (yes) 96 (49%) 20 (44%) 40 (55%) 11 (42%) 25 (48%) 0·61
Onset diagnosis (non-aﬀ ective) 211 (82%) 47 (87%) 82 (80%) 30 (86%) 52 (81%) 0·64
Medication prescribed at onset (yes) 240 (94%) 52 (96%) 96 (93%) 33 (94%) 59 (92%) 0·82
Type of medication at onset  0·46
Second-generation antipsychotic 236 (98%) 52 (100%) 94 (98%) 33 (100%) 57 (97%) ..
First-generation antipsychotic 4 (2%) 0 2 (2%) 0 2 (3%) ..
Data are n (%) or mean (SD). *p value estimates from Kruskal-Wallis test for means and χ² tests for independence for percentages to compare all cannabis groups. †Missing 
data for three participants. 
Table 1: Baseline characteristics
For R software see http://
www.R-project.org/
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2 years. Out of participants with pre-onset or post-onset 
cannabis use, only two (1%) of 153 participants started 
using cannabis after the onset, and most (97 [63%]) of 
these had used cannabis regularly before the onset of 
illness (appendix). The diﬀ erent subgroups based on 
pattern of cannabis use (table 1) diﬀ ered in the age of 
onset of their psychosis (Kruskal-Wallis test p=0·02) and 
in ethnic origin (χ²=25·98; p<0·0001) and sex (χ²=19·34; 
p=0·0002) distribution. Of those baseline characteristics 
assessed, only non-white ethnic origin was associated 
with risk of relapse (χ²=6·46, p=0·01; appendix).
Risk of relapse diﬀ ered across all groups (χ²=15·33; 
p=0·009). The greatest risk was recorded in continued 
high-frequency users of high-potency cannabis (skunk-
like), and the lowest was in former cannabis users 
currently abstaining (18 [58%] vs 13 [24%], respectively). 
Former cannabis users had the highest rate of community 
treatment only, requiring no referral for crisis intervention 
or inpatient care (table 1). By contrast, low-frequency and 
high-frequency users of high-potency (skunk-like) 
cannabis were more likely to experience compulsory 
admissions than former cannabis users (29% and 38% vs 
7%). We noted an eﬀ ect of pattern of cannabis use on 
number of relapses (p=0·01), length of relapses (p=0·009), 
time to relapse (p=0·02), and care intensity (p=0·005; 
table 2). Kaplan-Meier curves suggested that the diﬀ erent 
groups signiﬁ cantly diﬀ ered with regard to their time to 
relapse (Kaplan-Meier p=0·007). High-frequency and 
skunk-like users were more likely to have an earlier 
relapse than the former (regular) user group (Kaplan-
Meier with Bonferroni correction p=0·006; ﬁ gure).
In multiple logistic regression analysis, continued 
high-frequency use of high-potency cannabis (indexed 
as at least daily use throughout the follow up) remained 
a signiﬁ cant predictor for relapse (OR 3·28; 95% CI 
1·22–9·18) when compared with former users (table 3). 
The eﬀ ect remained signiﬁ cant when medication non-
adherence was included in the model (OR 2·73; 95% CI 
1·02–7·56), although this eﬀ ect was reduced in 
magnitude when compared with the odds from 
simple logistic regression analysis (ORsimple 4·37; 95% CI 
1·72–11·85). None of the other cannabis groups were 
diﬀ erent in their risk of relapse when compared with 
former users. In those risk models, only three other 
predictors remained signiﬁ cant, including non-white 
ethnic origin, care intensity at onset, and antipsychotic 
medication non-adherence (table 3). The results from 
the other multiple regression analyses conﬁ rmed that 
the adverse eﬀ ects of continued high-frequency skunk-
like use were also evident on the number of relapses, 
time to relapse, and a higher care intensity at follow up, 
while controlling for the above confounders. 
Including medication adherence into the model 
did not substantially change the results, although 
high-frequency skunk-like use remained a signiﬁ cant 
predictor only for length of relapse in this model 
(table 3). In propensity score-matched analyses 
Relapse 
(yes)*
Number of 
relapses†
Length of 
relapses†‡
Time to 
relapse†‡
Care intensity at follow up*
0 1 2 3
Former (regular) user 13 (24%) 0·35 (0·73) 0·59 (1·74) 20·86 (6·55) 40 (74%) 1 (2%) 9 (17%) 4 (7%)
Never (regular) user 31 (30%) 0·43 (0·74) 0·66 (1·46) 20·24 (6·57) 59 (57%) 13 (13%) 16 (16%) 15 (15%)
Intermittent user 14 (40%) 0·51 (0·70) 1·66 (3·53) 18·75 (6·88) 16 (46%) 5 (14%) 4 (11%) 10 (29%)
Continued user (hash-like) 4 (44%) 0·67 (1·00) 1·11 (2·07) 21·23 (5·22) 5 (56%) 0 1 (11%) 3 (33%)
Continued user
(skunk-like/low frequency)
13 (54%) 0·62 (0·65) 1·69 (3·34) 20·27 (4·67) 11 (46%) 0 4 (17%) 9 (38%)
Continued user
(skunk-like/high frequency)
18 (58%) 0·87 (0·92) 1·71 (2·85) 16·03 (8·21) 12 (39%) 1 (3%) 9 (29%) 9 (29%)
Data are n (%) or mean (SD). *χ² test for independence to compare all groups for risk of relapse (p=0·009, χ²=15·33) and care intensity at follow up (p=0·004,  χ²=33·49) 
†Kruskal-Wallis test to compare all groups in number of relapses (p=0·01), length (months) of relapses (p=0·009), time (months) to relapse (p=0·02). ‡Median and IQR are 
reported in the appendix (p 17). Care intensity at follow up: 0=required only community treatment without crisis intervention; 1=required crisis intervention without hospital 
admission; 2=required hospital admission without compulsory admission; 3=required compulsory hospital admission .
Table 2: Cannabis use pattern and relapse outcome
Figure: Kaplan-Meier curves of cannabis use pattern and time to relapse
p values are estimated from the log-rank tests to compare the diﬀ erent groups (reference group is the former 
[regular] user group). *Bonferroni-corrected signiﬁ cance level.
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considering all covariates (appendix), the eﬀ ect of high-
frequency skunk-like use was reduced in its magnitude 
but remained a signiﬁ cant predictor for risk of relapse 
and care intensity at follow up.
Several other predictors were signiﬁ cantly linked to 
relapse in the multiple regression analyses (table 3). 
Ethnic origin and medication non-adherence remained 
signiﬁ cant predictors in all models, including risk of 
relapse, number and length of relapses, time to relapse, 
and care intensity at follow up. Number of relapses was 
predicted by cigarette use and other illicit drug use. Finally, 
higher care intensity at onset was associated with risk of 
relapse, an increase in number of relapses and increase of 
length of relapse, as well as a higher care intensity 
throughout the 2 years following the onset of illness.
Further analyses using the continued user group 
(skunk-like/high-frequency) as the reference group 
showed that this group relapsed earlier than did the 
continued user (hash-like; b=0·29; 95% CI 0·01–0·58) 
and continued user (skunk-like/low frequency; b=0·27, 
95% CI 0·06–0·48) and never (regular) user groups 
(b=0·21, 95% CI 0·04–0·39; appendix).
Discussion
For the ﬁ rst time, this study of outcome in patients after 
their ﬁ rst episode of psychosis investigated the eﬀ ect of 
diﬀ erent patterns of cannabis use on risk of relapse by 
incorporating information about continuation, frequency, 
and type of cannabis used. Our results suggest that eﬀ ects 
of cannabis use on outcome vary, depending on speciﬁ c 
Risk of relapse Number of relapses Length of relapses Time to relapse Care intensity at follow-up
OR† 95% CI p value IRR‡ 95% CI p value b§ 95% CI p value b§ 95% CI p value OR¶ 95% CI p value
Model 1* (n=256)
Never (regular) 
user
1·24 0·53 to 3·03 0·63 1·27 0·70 to 2·29 0·43 –0·01 –0·81 to 0·79 0·99 –0·01 –0·15 to 0·13 0·92 2.01 0·91 to 4·60 0·09
Intermittent 
user
1·76 0·67 to 4·64 0·25 1·22 0·64 to 2·34 0·54 0·78 –0·09 to 1·66 0·07 –0·06 –0·23 to 0·10 0·46 2.78 1·14 to 6·91 0·03
Continued user 
(hash-like)
1·82 0·36 to 8·76 0·45 1·13 0·43 to 2·97 0·80 –0·33 –1·84 to 1·25 0·65 0·07 –0·20 to 0·35 0·60 2.40 0·51 to 10·44 0·25
Continued user 
(skunk-like/low 
frequency)
2·42 0·80 to 7·52 0·12 1·11 0·54 to 2·31 0·77 0·41 –0·64 to 1·49 0·41 0·05 –0·14 to 0·25 0·60 3.12 1·09 to 9·08 0·03
Continued user 
(skunk-like/high 
frequency)
3·28 1·22 to 9·18 0·02 1·77 0·96 to 3·25 0·07 0·61 –0·31 to 1·55 0·17 –0·22 –0·40 to –0·04 0·02 3.16 1·26 to 8·09 0·01
Ethnic origin 
(non-white)
2·36 1·23 to 4·69 0·01 1·82 1·16 to 2·85 0·01 0·97 0·35 to 1·59 0·002 –0·12 –0·23 to –0·01 0·03 1.94 1·08 to 3·54 0·03
Women 1·42 0·78 to 2·60 0·26 1·20 0·82 to 1·74 0·35 –0·27 –0·83 to 0·30 0·33 –0·04 –0·14 to 0·06 0·44 1.51 0·88 to 2·61 0·13
Other illicit drug 1·79 0·68 to 4·76 0·24 1·79 1·05 to 3·04 0·03 0·70 –0·17 to 1·60 0·10 –0·11 –0·28 to 0·07 0·23 1.43 0·60 to 3·41 0·42
Cigarette use 1·49 0·78 to 2·83 0·23 1·73 1·12 to 2·67 0·01 0·37 –0·17 to 0·92 0·20 –0·07 –0·18 to 0·04 0·24 1.66 0·92 to 3·02 0·09
Age of onset 1·01 0·97 to 1·04 0·78 1·00 0·97 to 1·02 0·82 –0·02 –0·05 to 0·01 0·30 0·00 –0·01 to 0·00 0·42 0.99 0·96 to 1·03 0·71
Alcohol use 1·72 0·75 to 3·94 0·20 1·14 0·69 to 1·88 0·60 –0·09 –0·85 to 0·69 0·81 –0·01 –0·15 to 0·14 0·90 1.96 0·95 to 4·08 0·07
Care intensity at 
onset
1·37 1·05 to 1·84 0·03 1·32 1·08 to 1·60 0·01 0·59 0·32 to 0·87 <0·001 –0·03 –0·07 to 0·02 0·22 1.33 1·03 to 1·73 0·03
Model 2|| (n=236)
Never (regular) 
user
1·28 0·58 to 2·88 0·55 1·13 0·65 to 1·98 0·65 0·20 –0·55 to 0·94 0·59 –0·01 –0·15 to 0·12 0·83 1·80 0·88 to 3·86 0·12
Intermittent 
user
1·57 0·58 to 4·29 0·37 1·22 0·62 to 2·42 0·56 0·78 –0·14 to 1·74 0·09 –0·06 –0·23 to 0·12 0·53 2·47 1·00 to 6·20 0·05
Continued user 
(hash-like)
2·54 0·50 to 12·98 0·25 1·74 0·67 to 4·52 0·25 0·57 –0·80 to 2·23 0·45 0·04 –0·25 to 0·33 0·80 3·30 0·70 to 14·76 0·12
Continued user 
(skunk-like/low 
frequency)
2·63 0·91 to 7·91 0·08 1·34 0·66 to 2·7 0·42 0·89 –0·06 to 1·91 0·08 0·03 –0·16 to 0·23 0·74 3·23 1·17 to 9·07 0·02
Continued user 
(skunk-like/high 
frequency)
2·73 1·02 to 7·56 0·05 1·74 0·94 to 3·24 0·08 0·98 0·09 to 1·90 0·04 –0·20 –0·38 to –0·01 0·03 2·93 1·17 to 7·47 0·02
Medication non-
adherence
3·25 1·79 to 6·09 <0·001 2·29 1·46 to 3·57 <0·001 0·57 –0·01 to 1·15 0·05 –0·15 –0·25 to –0·05 0·01 3·36 1·93 to 6·00 <0·001
Reference group refers to former (regular) users. OR=odds ratio. IRR=incidence rate ratio. *Medication non-adherence not included as a covariate. †Estimated from multiple logistic regression analysis. ‡Estimated 
from negative binomial regression. §Coeﬃ  cient estimate from negative binomial regression. ¶Estimated from multiple ordinal regression analysis. ||Only medication non-adherence included as a covariate.
Table 3: Multiple regression analyses of cannabis use pattern and relapse outcome
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cannabis use proﬁ le. Whereas former regular cannabis 
users who stopped using the substance regularly after the 
onset of psychosis had the lowest risk of relapse, those 
who continued to use at least on a monthly basis were 
most likely to experience a relapse. More speciﬁ cally, 
continued users of high-potency (skunk-like) cannabis 
who were using on a daily basis had the highest risk of 
relapse of psychosis when compared to former cannabis 
users. This eﬀ ect was independent of other putative risk 
factors for poor outcome, including ethnic origin, sex, age 
of onset, alcohol, cigarette and illicit drug use, and care 
intensity at onset (appendix). Furthermore, high-
frequency skunk-like users had more relapses, longer 
durations of hospital stay, shorter times to relapse, and 
more severe (as indexed by care intensity at follow up) 
relapses, when compared with former users. More 
rigorous adjustment for confounders using propensity 
score matching showed similar results, with high-
frequency users having a 1·9 times higher risk of relapse 
of psychosis. This eﬀ ect is similar in its magnitude, albeit 
in the opposite direction, to the eﬀ ect of antipsychotic 
medication treatment on risk of relapse in psychosis (eg, 
2·4 times higher risk for placebo vs drug-treated patients16).
High-frequency skunk-like users also relapsed earlier 
than hash-like and low-frequency skunk-like continued 
cannabis users and never (regular) users. Together, these 
results extend previous observational2,17 and experimental 
evidence9 of dose–response eﬀ ects of cannabis in patients 
with psychosis to demonstrate that the eﬀ ects of cannabis 
use on outcome in psychosis depend on the type of 
cannabis consumed as well as frequency of use. 
This ﬁ nding is consistent with similar evidence on the 
onset of psychosis.10 High-potency cannabis has become 
dominant in the UK.18 It has higher levels of 
delta-9-tetrahydrocannabiniol (THC), the main psycho-
togenic ingredient in cannabis, which modulates the 
neural substrates implicated in psychosis.8,19 Furthermore, 
high-potency cannabis has minimal concentrations of 
cannabidiol (CBD),18 which ameliorates some of the 
eﬀ ects of THC20 and might have antipsychotic 
properties.21 High relapse rates and short time to relapse 
in high-frequency skunk users might be the result of a 
failure to respond to antipsychotic treatment4 either on 
its own or in combination with an increase in the severity 
of psychotic symptoms in those frequently exposed to a 
higher dose of THC,9 which were not investigated in the 
present study. This result might explain why some 
previous studies that did not diﬀ erentiate between the 
type of cannabis did not report an association between 
cannabis use and relapse.22 It might also explain why the 
risk estimate noted in our study for the high-dose group 
(high-frequency/skunk-like) was substantially higher 
compared with the pooled odds from previous studies 
that investigated the risk of cannabis on relapse 
(ORsimple 4·37 vs ORsimple 1·97).7 The ﬁ nding of no diﬀ erence 
in outcome between cannabis users who remained 
abstinent after the onset of psychosis and the non-user 
group suggests that the eﬀ ects of previous cannabis use 
on outcome in psychosis are not irreversible7 and that 
investigations need to move beyond the eﬀ ects of lifetime 
cannabis use or cannabis use assessed at onset only.23 
Future investigations should focus on changes in pattern 
of use and type of cannabis used after psychosis onset 
because these might be the key factors driving adverse 
outcomes associated with cannabis use in patients with 
psychosis.
Our data suggest that high-frequency use of potent 
forms of cannabis will adversely aﬀ ect outcome even in 
treatment-adherent patients, perhaps by reducing the 
eﬀ ectiveness of antipsychotics.3 Together, these results 
are opposed to non-causal explanations for the association 
between frequent (daily) use of high-potency skunk-like 
cannabis and outcome, such as reverse causation or 
confounding, and suggest that change in cannabis use 
after the onset of psychosis is an important determinant 
for outcome in psychosis. In view of the lack of eﬀ ective 
psychological24 or pharmacological25 treatments for 
comorbid cannabis users with psychosis, our results 
suggest that reducing frequency of use or shifting to less 
potent forms might be useful intervention strategies in 
psychotic patients who are otherwise unable to stop 
using cannabis.
This study has certain limitations, such as comprising a 
selective subset of inner city, ﬁ rst episode of psychosis 
patients more likely to engage with community mental 
health services and having less severe psychopathology, 
bias from refusal to take part in the study, use of 
retrospective self-report measures of cannabis and other 
substance use leading to under-reporting, modest sized 
(n=8) continued hash-like (resin) user group, and not 
controlling for the eﬀ ect of migrant status, or the eﬀ ect of 
type and dose of antipsychotic medication on relapse. 
However, as discussed in greater detail in the appendix, 
these factors are unlikely to have aﬀ ected the direction of 
our results.
Nevertheless, this is the ﬁ rst study that suggests that 
those who continue to use high-potency cannabis even 
after the onset of their psychosis are at the greatest risk of 
relapse of their illness and of experiencing more frequent 
and earlier relapses that require more intensive psychiatric 
care than those who do not continue cannabis use.
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